30 September 2026
Lilly's two-drug obesity combo beat its own top seller in a mid-stage trial
Patients on the highest-dose combo lost an average of 23.3% of their body weight over 48 weeks, versus 14.8% on tirzepatide alone, but more of them quit over side effects.
Eli Lilly says pairing a new drug with its blockbuster obesity shot helped people lose a lot more weight than the shot on its own. The catch: more people in the combo groups stopped treatment because of side effects.
What happened
The test was a 48-week Phase 2 trial (the middle stage of drug testing, run on a few hundred people rather than thousands) in adults with obesity and Type 2 diabetes. That group often finds weight loss harder than others do.
The combo joins eloralintide, an experimental drug aimed at amylin (a hormone that helps you feel full), with tirzepatide, the active ingredient in Zepbound and Mounjaro. Tirzepatide already works on two other gut hormones, GLP-1 and GIP.
At the top dose, 9 milligrams of eloralintide plus 15 milligrams of tirzepatide, people lost up to 23.3% of their weight on average, or about 54 pounds. A 15-milligram dose of tirzepatide alone produced 14.8%, or 34.4 pounds. Eloralintide alone reached up to 12.3%, or 28.6 pounds.
Blood sugar also improved. The combo cut A1C, a common measure of blood sugar control, by up to 2.9 percentage points on average. Tirzepatide alone managed up to 2.4 and eloralintide alone up to 1.4.
The side-effect question
Between 10.8% and 27% of combo patients, depending on dose, left the trial because of side effects. For tirzepatide alone the figure was 2.9%. Lilly said the most common problems were stomach-related, mostly mild or moderate, and showed up mainly when doses were raised.
Ken Custer, who leads Lilly's cardiometabolic unit, told CNBC that dropout rates in Phase 2 are not a good guide to tolerability. He noted that high-dose tirzepatide showed a similar rate, around 25%, in a 2018 mid-stage trial. Lilly plans to change the dosing in later trials.
Why it matters
Lilly is worth about $1.1 trillion on Noorult's data, and tirzepatide is its top-selling drug, so anything that could extend it draws attention. Lilly's latest filings show about $79.7 billion of revenue and $26.7 billion of net income. The company also said the combo could be a rival to Novo Nordisk's CagriSema, which pairs amylin and GLP-1 drugs.
Phase 2 results are an early signal. Many drugs that look good here change once much larger Phase 3 trials begin.
What to watch
- Phase 3 trials, which Lilly says will start by the end of 2026.
- A plan to test a single injection containing both drugs.
- How dropout rates look once dosing is adjusted.
Lilly's financial history is on its Noorult company page.
The companies in this story
Based on reporting by CNBC: Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial. Facts, not advice.
More news
- Anthropic's IPO, in numbers: 825 million shares at $70 to $78, and a $1.4 trillion price tag
- Trump says the Nvidia scandal didn't endanger US security, and stands by Lutnick
- Nvidia's first earnings without Huang: what Kress will be asked on Tuesday
- Buffett gives away $5.5 billion of Berkshire stock in his Thanksgiving letter
- Banks are using AI to trim back offices. Proof that it adds revenue is harder to find
- IMF chief says the world economy leans too hard on AI as circular deals top $1 trillion